What does Apotheek GYSENBERGS do?

Apotheek GYSENBERGS is a pharmacy in Nieuwerkerken (Limb.). Private Limited, started on 22 June 1990, 1 establishment.

What is the address of Apotheek GYSENBERGS?

The registered office of Apotheek GYSENBERGS is located at Dorpsstraat 16, 3850 Nieuwerkerken (Limb.).

Is Apotheek GYSENBERGS still active?

Yes. According to the CBE (31 October 2026) Apotheek GYSENBERGS is active, legal situation “Normale toestand”, started on 22 June 1990.

Is Apotheek GYSENBERGS registered on Peppol?

Yes, Apotheek GYSENBERGS is registered on the Peppol network with ID 0208:0441482533.

What is the enterprise number of Apotheek GYSENBERGS?

The enterprise number of Apotheek GYSENBERGS is BE0441482533.

When was Apotheek GYSENBERGS founded?

Apotheek GYSENBERGS was founded on 22 June 1990.

Who are the directors of Apotheek GYSENBERGS?

According to the 2025 annual accounts, the directors of Apotheek GYSENBERGS are: Bos & Berg.

Is Apotheek GYSENBERGS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 22 June 1990; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Apotheek GYSENBERGS make in 2025?

Apotheek GYSENBERGS posted a profit after taxes of € 59,291 in financial year 2025.

What is the revenue of Apotheek GYSENBERGS?

As a small company, Apotheek GYSENBERGS is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 177,184.

How much does an employee at Apotheek GYSENBERGS earn?

The average wage cost per full-time employee at Apotheek GYSENBERGS was € 33,200 in 2025: staff costs of € 76,343 for 2.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Apotheek GYSENBERGS have?

According to the 2025 annual accounts, Apotheek GYSENBERGS has 2.3 full-time equivalents (FTE).

Apotheek GYSENBERGS (Private Limited)

Dossier Apotheek GYSENBERGS, printed on 31 October 2026 from databakkes.be/en/0441482533/apotheek-gysenbergs. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 36 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Apotheek GYSENBERGS from Nieuwerkerken (Limb.), company number BE0441482533, closed financial year 2025 with a result of € 59,291 after tax. For that financial year Apotheek GYSENBERGS recorded a gross margin of € 177,184 and equity of € 36,727. Compared with financial year 2024, the result moved from € 2,653 to € 59,291. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 5, 2026.

What it is worth Growing

€ 36,727

▲ 13% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 59,291

▲ € 56,638 vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 2,402

▼ 13% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 55,000 paid out

93 % of the profit went to the shareholders, mostly to BOS & BERG (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

2.3

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 76,343

▼ 24% vs 2024

€ 33,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 11,697

▼ 11% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 5 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 331,982

▼ 10% vs 2024

€ 17,188 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.

Owed to suppliers

€ 24,709

▼ 37% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 14,284

▼ 18% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 106,842 Gross margin 2022: € 106,842 First fiscal year in the series	€ 137,528 Gross margin 2023: € 137,528 ▲ 29% vs 2022 (€ 106,842) Favourable step	€ 143,047 Gross margin 2024: € 143,047 ▲ 4% vs 2023 (€ 137,528) Favourable step	€ 177,184 Gross margin 2025: € 177,184 ▲ 24% vs 2024 (€ 143,047) Favourable step	▲ 24%
Profit after taxes	€ -1,385 Profit after taxes 2022: € -1,385 First fiscal year in the series	€ 3,752 Profit after taxes 2023: € 3,752 ▲ € 5,137 vs 2022 (€ -1,385) Favourable step	€ 2,653 Profit after taxes 2024: € 2,653 ▼ 29% vs 2023 (€ 3,752) Unfavourable step	€ 59,291 Profit after taxes 2025: € 59,291 ▲ € 56,638 vs 2024 (€ 2,653) Favourable step	▲ € 56,638
Equity	€ 26,031 Equity 2022: € 26,031 First fiscal year in the series	€ 29,783 Equity 2023: € 29,783 ▲ 14% vs 2022 (€ 26,031) Favourable step	€ 32,436 Equity 2024: € 32,436 ▲ 9% vs 2023 (€ 29,783) Favourable step	€ 36,727 Equity 2025: € 36,727 ▲ 13% vs 2024 (€ 32,436) Favourable step	▲ 13%
Total debts	€ 467,516 Total debts 2022: € 467,516 First fiscal year in the series	€ 459,765 Total debts 2023: € 459,765 ▼ 2% vs 2022 (€ 467,516) Favourable step	€ 428,777 Total debts 2024: € 428,777 ▼ 7% vs 2023 (€ 459,765) Favourable step	€ 426,709 Total debts 2025: € 426,709 Unchanged (€ 428,777) Favourable step
Cash	€ 16,225 Cash 2022: € 16,225 First fiscal year in the series	€ 19,550 Cash 2023: € 19,550 ▲ 20% vs 2022 (€ 16,225) Favourable step	€ 2,749 Cash 2024: € 2,749 ▼ 86% vs 2023 (€ 19,550) Unfavourable step	€ 2,402 Cash 2025: € 2,402 ▼ 13% vs 2024 (€ 2,749) Unfavourable step	▼ 13%
Land & buildings	€ 89,152 Land & buildings 2022: € 89,152 First fiscal year in the series	€ 69,508 Land & buildings 2023: € 69,508 ▼ 22% vs 2022 (€ 89,152) Unchanged	€ 55,391 Land & buildings 2024: € 55,391 ▼ 20% vs 2023 (€ 69,508) Unchanged	€ 38,487 Land & buildings 2025: € 38,487 ▼ 31% vs 2024 (€ 55,391) Unchanged	▼ 31%
Retained profit	€ 6,031 Retained profit 2022: € 6,031 First fiscal year in the series	€ 9,783 Retained profit 2023: € 9,783 ▲ 62% vs 2022 (€ 6,031) Favourable step	€ 12,436 Retained profit 2024: € 12,436 ▲ 27% vs 2023 (€ 9,783) Favourable step	€ 16,727 Retained profit 2025: € 16,727 ▲ 35% vs 2024 (€ 12,436) Favourable step	▲ 35%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 55,000 Dividend 2025: € 55,000 Unchanged (€ 0) Unchanged
Bank debt	€ 387,944 Bank debt 2022: € 387,944 First fiscal year in the series	€ 388,761 Bank debt 2023: € 388,761 Unchanged (€ 387,944) Unfavourable step	€ 367,170 Bank debt 2024: € 367,170 ▼ 6% vs 2023 (€ 388,761) Favourable step	€ 331,982 Bank debt 2025: € 331,982 ▼ 10% vs 2024 (€ 367,170) Favourable step	▼ 10%
Balance sheet total	€ 493,547 Balance sheet total 2022: € 493,547 First fiscal year in the series	€ 489,548 Balance sheet total 2023: € 489,548 ▼ 1% vs 2022 (€ 493,547) Unchanged	€ 461,213 Balance sheet total 2024: € 461,213 ▼ 6% vs 2023 (€ 489,548) Unchanged	€ 463,436 Balance sheet total 2025: € 463,436 Unchanged (€ 461,213) Unchanged
Employees (FTE)	2.2 Employees (FTE) 2022: 2.2 First fiscal year in the series	2.3 Employees (FTE) 2023: 2.3 ▲ 0.1 vs 2022 (2.2) Unchanged	2.3 Employees (FTE) 2024: 2.3 Unchanged (2.3) Unchanged	2.3 Employees (FTE) 2025: 2.3 Unchanged (2.3) Unchanged

Key figures of Apotheek GYSENBERGS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Apotheek GYSENBERGS?

What happened at Apotheek GYSENBERGS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 5, 2026 New annual accounts for financial year 2025: profit of € 59,291 (▲ € 56,638 vs 2024). Source: NBB ↗
2006 Bos & Berg became a director. NBB
Sep 24, 1990 New establishment in Nieuwerkerken (Limb.). KBO
Jun 22, 1990 Start of the company according to the CBE. KBO

In short

From € 1,385 loss in 2022 to € 59,291 profit in 2025.

Paid € 2,241 in corporate taxes since 2022.

Best year ever: 2025, with € 59,291 profit.

On average € 77,000 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

BOS & BERG 100%

The stake of BOS & BERG comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Apotheek GYSENBERGS

Behind Apotheek GYSENBERGS is Bos & Berg. The shares are held by BOS & BERG (100%).

Directors

According to the 2025 annual accounts

Bos & Berg

Director · represented by Veerle Gysenbergs

since 2006

Shareholders

BOS & BERG

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Dorpsstraat 16

3850 Nieuwerkerken (Limb.)

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

BOS & BERG same network

€ 52,284 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0441.482.533

VAT number

BE 0441.482.533

Registered office

Dorpsstraat 16, 3850 Nieuwerkerken (Limb.)

Names & denominations

Apotheek GYSENBERGS

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

22 June 1990

Peppol

Active · Active since 2 Apr 2025

Contact

011 31 16 66

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

Apotheek GYSENBERGS

Warning lights

Financials

What happened to Apotheek GYSENBERGS?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions